Asymptomatic infection in a proof-of-concept longitudinal study on SARS-CoV-2 vaccine recipients
Shih, C.; Liao, Y.-Z.; Hsu, C.-Y.; Tsai, Y.-C.; Lin, M.-Y.; Chiou, H.-Y. C.; Kuan, W.-H.; Chang, C.-H.; Liou, A.-T.; Chou, Y.-C.; Sheen, F.-Z.; Lin, H.-J.; Tsai, J.-J.; Lin, P.-C.; Yu, M.-L.; Chuang, W.-L.; Lee, J.-J.; Chang, J.-M.; Hwang, S.-J.; Shih, J.; Hung, W.-C.; Hou, M.-F.; Chong, I.-W.; Jong, Y.-J.; Chang, J.-S.
Show abstract
Individuals with asymptomatic SARS-CoV-2 infection can unknowingly transmit the virus, yet identifying such infections in vaccinated populations remains challenging. We conducted a longitudinal study of 129 vaccine recipients immunized with various combinations of SARS-CoV-2 spike (S) protein vaccine platforms. Sera were collected before the first dose (v1), at 2 weeks (v7) and 6 months (v8) after the third dose. Taiwans first major COVID-19 outbreak occurred between v7 and v8. We measured anti-nucleocapsid (anti-N) and anti-S IgG antibody titers by ELISA and assessed virus-neutralizing activity using live virus and pseudovirus assays. By developing an iterative serial screening method, we identified asymptomatic infections among unconfirmed cases. Our v7-v8 paired cohort resolved into three distinct groups: confirmed cases (21%), asymptomatic infections (17%), and uninfected cases (62%). In normalized v8 sera, confirmed cases exhibited an anti-S+++/anti-N+++ phenotype, while uninfected cases showed an anti-S+/anti-N+ phenotype. Statistical analysis validated a distinct asymptomatic group characterized by intermediate anti-S but baseline anti-N antibody levels (anti-S++/anti-N+). This approach enables more accurate estimates of infection prevalence and vaccine efficacy.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 96%
- Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies 96%
- Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2 96%
Similar papers in this journal
- Cross neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2 96%
- Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and heterologous variants 96%
- Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine 96%
Similar papers in this journal
- Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection 97%
- Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants 96%
- mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2 95%
Similar papers in this journal
- Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection 96%
- Soluble Spike DNA vaccine provides long-term protective immunity against SAR-CoV-2 in mice and nonhuman primates 95%
- Longitudinal analyses after COVID-19 recovery or prolonged infection reveal unique immunological signatures after repeated vaccinations 95%
Similar papers in this journal
- Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms 96%
- Evaluation of antibody kinetics and durability in health subjects vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China 95%
- A Remarkable Genetic Shift in a Transmitted/Founder Virus Broadens Antibody Responses Against HIV-1 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.